Actuate therapeutics announces positive interim phase 2 data of elraglusib in first line treatment of metastatic pancreatic cancer

Chicago and fort worth, texas, dec. 17, 2024 (globe newswire) -- actuate therapeutics, inc. (nasdaq: actu) (“actuate” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (gsk-3Β), today announced new positive data from its ongoing and fully enrolled randomized phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel (gnp) in first line treatment of metastatic pancreatic ductal adenocarcinoma (mpdac) (actuate-1801 part 3b).
ACTU Ratings Summary
ACTU Quant Ranking